#SunPharma's shares fall after it announces it'll buy #ConcertPharmaceuticals for $576 million.
#SunPharma enters into an exclusive distribution, licence, & supply agreement with Philogen to commercialise Nidlegy in EU, Australia & New Zealand
Sun Pharma (#SunPharma_Live) gets approval from Health Canada for Absorica LD, an #acne drug
#1QWithCNBCTV18 | #SunPharma will report its #Q1 earnings today. The street expects the pharma giant to report 8% growth in profit. Growth to be led by specialty portfolio in US & other international markets https://t.co/IHFSTRmZXC
#1QWithCNBCTV18 | #SunPharma reports #Q1 earnings
⭕️ Net profit at ₹2,022.5 cr vs CNBC-TV18 poll of ₹2,090.4 cr https://t.co/7V5jTbEJLL
⭕️ Net profit at ₹2,022.5 cr vs CNBC-TV18 poll of ₹2,090.4 cr https://t.co/7V5jTbEJLL
#1QWithCNBCTV18 | #SunPharma report #Q1 earnings
▶️One-time loss at ₹323 cr
▶️Other income at ₹204.4 cr vs ₹2.1 cr (YoY) https://t.co/KqLPNwnBB8
▶️One-time loss at ₹323 cr
▶️Other income at ₹204.4 cr vs ₹2.1 cr (YoY) https://t.co/KqLPNwnBB8
#OnCNBCTV18 | Taro Board has appointed a special committee on Sun's offer. Not giving specific guidance on speciality business. Committed to #FY24 #guidance of high-single digit growth in revenue, says CS Muralidharan of #SunPharma
#1QWithCNBCTV18 https://t.co/ayJ1dWGXDh
#1QWithCNBCTV18 https://t.co/ayJ1dWGXDh
Sun Pharma #FY24Outlook | Company expect high-single-digit consolidated topline growth for #FY24
#SunPharma https://t.co/uF7qEERZEc
#SunPharma https://t.co/uF7qEERZEc
#SunPharma subsidiary #TaroPharma reported a 12.5% jump in its overall sales for the January-March quarter to $164.9 million, writes @ekta_batra
▶️Gross profit up 16% at $87.4 million vs $75.7 million (YoY)
▶️Operating income down 5% at $8.8 million vs $9.3 million (YoY)
▶️Net income at $15.1 million vs $6.9 million (YoY)
▶️Gross profit up 16% at $87.4 million vs $75.7 million (YoY)
▶️Operating income down 5% at $8.8 million vs $9.3 million (YoY)
▶️Net income at $15.1 million vs $6.9 million (YoY)
#SunPharma & Israel-based Moebius Medical granted US FDA Fast Track designation (FTD) to MM-II (Large Liposomes of DPPC and DMPC), used for the treatment of osteoarthritis knee pain